Gilead’s Covid drug is mediocre. It will be a blockbuster anyway.

Gilead’s Covid drug is mediocre. It will be a blockbuster anyway. The company said that by December, it expected to have produced enough drug to treat 2 million patients and that it was studying an inhaled form of the drug that could expand its use to outpatients. https://ift.tt/eA8V8J

Comments

Post a Comment

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

The PIL argued that persons with mental illnesses were chained in a faith-based mental asylum in Budaun district of Uttar Pradesh in violation of provisions of the Mental Health Care Act 2017. The court examined the photos of such patients calling it a matter of great concern. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/hG1drmq via gqrds
Read more

Hospital-insurer conflict: Will latest circular by NMC help in reducing the pain of health insurance policyholders?

The rational use of medicines and diagnostics will directly benefit policyholders by lowering their out-of-pocket expenses. At the same time, streamlined care will result in faster recovery and fewer complications, believes Roy. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/OG5T7Mw via gqrds
Read more

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018

According to the National Health Authority's (NHA) annual report 2024-25, over 40.45 crore Ayushman cards were issued till March 31, covering 14.69 crore families and eighty-two per cent of beneficiaries are from rural areas, with 94 per cent having Aadhaar-verified cards, ensuring authenticity and inclusivity, the report stated. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/JRnLlcK via gqrds
Read more